Company profile
HARROW, INC.
NASDAQ:HROWBiotechnology: Pharmaceutical Preparations
Drug pipeline (16)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| APRACLONIDINE HYDROCHLORIDE | approved | — | 0 | — |
| Cetirizine hydrochloride | approved | — | 2 | approved |
| CHLOROPROCAINE HYDROCHLORIDE | approved | — | 0 | — |
| Clobetasol propionate | approved | — | 0 | — |
| Cyclosporine | approved | — | 17 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07456826 | phase4 | enrolling_by_invitation | 2026-03-31 | 2026-08-01 | Harrow Inc | Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections |
| NCT05934253 | phase4 | completed | 2023-07-15 | 2024-01-15 | Harrow Inc | The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine |
| NCT07588074 | phase4 | completed | 2021-05-01 | 2021-06-30 | Harrow Inc | Tolerability Comparison of Flarex to Lotemax SM |
FDA applications (20)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 013422 | NDA | HARROW EYE LLC | ||||
Loading… | ||||||
| NDA 017468 | NDA | HARROW EYE LLC | ||||
Loading… | ||||||
| NDA 019079 | NDA | HARROW EYE LLC | ||||
Loading… | ||||||
| NDA 019779 | NDA | HARROW EYE LLC | ||||
Loading… | ||||||
| NDA 020258 | NDA | HARROW EYE LLC | ||||
Loading… | ||||||